Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-832-6 | CAS number: 75-02-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study was selected as the key study because the information provided for the hazard endpoint is sufficient for the purpose of classification and labelling and/or risk assessment.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- Remarks:
- The study was conducted according to the guideline in effect at the time of study conduct.
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.5375 (In Vitro Mammalian Chromosome Aberration)
- Deviations:
- no
- Remarks:
- The study was conducted according to the guideline in effect at the time of study conduct.
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- Fluoroethylene
- EC Number:
- 200-832-6
- EC Name:
- Fluoroethylene
- Cas Number:
- 75-02-5
- Molecular formula:
- C2H3F
- IUPAC Name:
- fluoroethene
- Details on test material:
- - Purity: 99.99%
Constituent 1
Method
Species / strain
- Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: Ham’s F12 medium without hyposanthine (F12 w/o hx) containing 5% dialyzed heat-inactivated foetal bovine serum without antibiotics. In cytotoxicity and chromosome aberration experiments, penicillin (50 units/mL) and streptomycin (50 micrograms/mL) were included in the culture medium.
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically checked for karyotype stability: no data
- Periodically "cleansed" against high spontaneous background: no data - Additional strain / cell type characteristics:
- other: BH4 clone of the CHO-K1 cell line
- Metabolic activation:
- with and without
- Metabolic activation system:
- Aroclor 1254-induced rat liver S9
- Test concentrations with justification for top dose:
- Chromosome aberration assay (without activation): 0, 10, 40, 70, and 100% (target concentrations); 0.0, 8.1, 42.9, 72.3, and 104.1% (analytical concentrations)
Chromosome aberration assay (with activation): 0, 10, 25, 50, and 75% (target concentrations); 0.0, 8.3, 25.9, 49.6, and 75.1% (analytical concentrations)
Confirmatory chromosome aberration assay (without activation): 0, 10, 40, 70, and 100% (target concentrations); 0.0, 8.8, 46.5, 77.8, and 111.4% (analytical concentrations)
Confirmatory chromosome aberration assay (with activation): 0, 10, 25, 50, and 75% (target concentrations); 0.0, 12.3, 35.4, 63.3, and 91.3% (analytical concentrations)
Controls
- Untreated negative controls:
- yes
- Remarks:
- Nitrogen
- Positive controls:
- yes
- Positive control substance:
- other: For trials without activation: 6.44 mM methane sulfonic acid, ethyl ester (ethylmethane sulfonate, EMS); phosphate buffered saline was used as the solvent. For trials with activation: approximately 2.5% vinyl chloride (VC) mixed with air.
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: The day following culture initiation, the medium was replaced with treatment medium. Specially designed 1.65 L glass chambers were used to expose the cell cultures. A separate chamber was used for each test level. Tissue culture flasks (4/test level) were uncapped and placed into the chambers immediately prior to the exposure period. The cells were incubated with the test material for 5 hours without activation or 2 hours with activation. During the treatment period, the flasks were incubated on a rocker panel to maximize exposure. After incubation, the flasks were flushed once with air, the treatment medium was removed, and the flasks were rinsed with fresh culture medium and incubation continued for 24-26 hours. Colcemid® was added to the medium approximately 2-3 hours before the end of this incubation period to arrest metaphase cells. Cell from pairs of like-treated flasks were collected and pooled in centrifuge tubes to form two replicate samples for harvest. The cells were then incubated for 15 minutes in a hypotonic solution of sodium citrate and fixed in two changes of 3:1 mixture of methanol and glacial acetic acid. Centrifugation was required between each of these steps and after the final fixation step. Cells were resuspended in fixative and one slide per culture prepared by applying an aliquot of the fixed cells onto microscope slides and air-drying them. The slides were stained by Giemsa and permanently mounted.
DURATION
- Exposure to the test substance began the day following cell plating in culture medium.
- Cells were incubated with the test substance for 4 hours (-S9 and +S9) and 20 hours (-S9).
- After incubation, the flasks were flushed once with air, the treatment medium removed, and the flasks rinsed with fresh culture medium. The incubation was continued for 24-26 hours. Colcemid® was added to the medium approximately 2-3 hours before the end of this incubation period.
SPINDLE INHIBITOR (cytogenetic assays): Colcemid®
STAIN (for cytogenetic assays): Giemsa
NUMBER OF REPLICATIONS: 2 independent trials
NUMBER OF CELLS EVALUATED: At least 100 metaphases per concentration level (50 from each duplicate culture).
DETERMINATION OF CYTOTOXICITY
- Method: A cytotoxicity assessment was conducted and fifty to 100 metaphase cells per test concentration were scanned and scored. Cell cycle delay was judged fo be present where marked increases in first metaphase cells were seen in the relative distribution of first metaphase, first-to-second metaphase, and second metaphase cells, as compared to the control. The cells were distinguished by their characteristic chromosome staining, resulting from differential uptake of 5-bromodeoxyuridine.
OTHER: A pair of flow meters was used to generate the appropriate test substance-nitrogen mixture. Atmospheric samples were drawn from each exposure chamber with a glass syringe and analyzed with a gas chromatograph equipped with a flame ionization detector. - Evaluation criteria:
- Assessment of a positive response was based on:
• A statistically significant increase (p < 0.05) in the percentage of cells with chromosomal aberrations was seen in one or more treatment groups relative to the negative control response.
• The observed increased frequencies were accompanied by a concentration-related increase.
• These effects must be reproducible (i.e., evident in both trials under activated or nonactivated conditions).
The test substance was judged negative if:
• There was neither a statistically positive response at a minimum of one test level nor a significant dose-related increase in chromosomal aberrations.
Results which do not meet these criteria for positive or negative assessments were evaluated on a case-by-case basis. - Statistics:
- For each trial the following were evaluated statistically: the number of structural aberrations, expressed on a per-cell basis; the percent abnormal cells; and the percent cells with more than one aberration. Chromatic and isochromatid gaps were recorded, but excluded from the calculations.
A Mann-Whitney U Test comparing each treatment level with the negative control was used to evaluate the data for aberrations per cell. The percent abnormal cells and percent cells with more than one aberration were evaluated using a Fisher Exact Test to compare each treatment level with the negative control. Statistical significance was judged at the 5% level.
Results and discussion
Test resultsopen allclose all
- Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- without
- Genotoxicity:
- ambiguous
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES:
Non-activated, cytotoxicity studies showed a significant cell cycle delay only at the relatively high concentration of 96.3%. With activation, moderate cell cycle delay at 52.1%, and severe cell cycle delay at 61.3% or more was observed. See Table 1 for complete results.
Trials Without Activation:
The initial evaluation of 100 cells per treatment level resulted in a statistically significant increase in the percent abnormal cells at only the highest test concentration in nonactivated Trial I; no significant treatment effects were detected in nonactivated Trial II (see Table 2). In an effort to clarify the discrepant findings in the nonactivated trials, an additional 100 cells per trial were scored from the negative control and the highest test substance concentration, where possible. (The data in the tables represent the total of all cells scored.) This analysis also yielded statistically significant increases at the highest test concentration in the first trial; aberrations per cell and percent abnormal cells were elevated. However, nonactivated Trial II remained negative. Since the actual test concentrations in both nonactivated trials were comparable, a combined analysis of percent abnormal cells for both trials was done. This showed a statistically significant (p= 0.04) increase at the highest test concentration. However, the aberration frequencies observed at this level fall in the range of historical control data for the assay. For this reason, and since the effect observed in nonactivated Trial I was not reproduced in Trial II, the test substance is considered equivocal without activation.
Trial With Activation:
The evaluation of 100 cells per test level showed statistically significant increases in aberrations per cell and percent abnormal cells at the three lowest test concentrations (see Table 3). In activated Trial II, the initial evaluation of 100 cells per treatment level showed no significant increases in aberration indices at any test concentration. To clarify the apparent discrepancy with activated Trial I, 100 additional cells per treatment level were scored from Trial II. This analysis (see Table 3) showed significant increases in percent cells with more than one aberration at 35.4 and 63.3% test substance atmospheres; increases in the other two aberration indices were not statistically significant. However, the occurrence at two treatment levels of several cells with more than one aberration was judged to represent confirmation of the positive findings in activated Trial I. Thus, the test substance is considered positive with activation. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information):
positive with metabolic activation
ambiguous without metabolic activation
The study and the conclusions which are drawn from it fulfil the quality criteria (validity, reliability, repeatability). The test substance exhibited clastogenic activity in CHO cells with S-9 activation. Without activation, the findings were equivocal. Under the conditions of this assay, the test substance is positive. - Executive summary:
The test substance was evaluated for clastogenic (chromosome-damaging) activity in Chinese hamster ovary (CHO) cells in vitro following 2-hour treatment with metabolic (S9) activation and 5-hour treatment without metabolic (S9) activation. Two independent trials were conducted. The maximum target concentration tested was 100%. Metaphase cells were evaluated and aberrations per cell, percent abnormal cells, and percent cells with > 1 aberration reported. Under nonactivated conditions, cytotoxicity studies showed significant cell cycle delay only at a test substance concentration of 96.3% (in nitrogen). With activation, moderate cell cycle delay was observed at 52.1% and severe cell cycle delay was evident at a test substance concentration of ≥ 61.3%. In the chromosome aberration studies, equivocal results were obtained following 5-hour nonactivated treatments. After 2-hour treatments with S-9, significant chromosome aberration induction was seen at test substance concentrations ranging from 8.3-63.3%. Under the conditions of this assay, the test substance is positive.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.